Fractyl Health, Inc. (NASDAQ:GUTS) Receives $5.40 Consensus Target Price from Analysts

Fractyl Health, Inc. (NASDAQ:GUTS) has received a consensus recommendation of “Hold” from the five analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $5.40.

Several analysts have issued reports on GUTS shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday, May 12th. Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research note on Thursday, March 26th. Morgan Stanley cut Fractyl Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $8.00 to $2.00 in a report on Thursday, January 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research report on Friday, April 24th.

Institutional Trading of Fractyl Health

Large investors have recently made changes to their positions in the stock. FNY Investment Advisers LLC purchased a new position in Fractyl Health during the third quarter valued at approximately $31,000. Jane Street Group LLC bought a new position in shares of Fractyl Health in the 2nd quarter worth $31,000. Accredited Investors Inc. purchased a new stake in shares of Fractyl Health during the 1st quarter worth $46,000. Scientech Research LLC purchased a new stake in shares of Fractyl Health during the 3rd quarter worth $49,000. Finally, Prelude Capital Management LLC bought a new stake in Fractyl Health during the third quarter valued at about $55,000.

Fractyl Health Trading Down 1.1%

GUTS stock opened at $0.91 on Friday. Fractyl Health has a twelve month low of $0.38 and a twelve month high of $3.03. The stock has a market capitalization of $144.31 million, a price-to-earnings ratio of -0.71 and a beta of 2.11. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 1.41. The firm’s fifty day simple moving average is $0.59 and its two-hundred day simple moving average is $1.12.

Fractyl Health (NASDAQ:GUTS) last released its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.23. As a group, analysts anticipate that Fractyl Health will post -0.6 earnings per share for the current year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.